more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Zacks News

Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet

by Zacks Equity Research Published on January 24,2023

According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

LLYNegative Net Change

Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance

by Zacks Equity Research Published on January 23,2023

Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.

pharmaceuticals

Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer

by Zacks Equity Research Published on January 23,2023

Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.

biotechs

FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug

by Zacks Equity Research Published on January 20,2023

The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.

Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds

by Kinjel Shah Published on January 20,2023

FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints

pharmaceuticals

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research Published on January 18,2023

In the latest trading session, Eli Lilly (LLY) closed at $352.01, marking a -1.6% move from the previous day.

LLYNegative Net Change

BAYRY or LLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on January 17,2023

BAYRY vs. LLY: Which Stock Is the Better Value Option?

Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?

by Zacks Equity Research Published on January 17,2023

Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research Published on January 17,2023

Sector ETF report for IHE

Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan

by Zacks Equity Research Published on January 16,2023

Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.

biotechs

State of California Sues Insulin Makers for Unfair Practices

by Zacks Equity Research Published on January 13,2023

The lawsuit aims to curb the skyrocketing cost of insulin charged by insulin manufacturers and pharmacy benefit managers companies. The State also seeks to recover some monetary compensation.

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research Published on January 12,2023

Eli Lilly (LLY) closed at $359.12 in the latest trading session, marking a -0.36% move from the prior day.

LLYNegative Net Change

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

by Zacks Equity Research Published on January 12,2023

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

LLYNegative Net Change

Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe

by Zacks Equity Research Published on January 11,2023

Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.

biotechs

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research Published on January 11,2023

Sector ETF report for IYH

Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research Published on January 10,2023

Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day.

consumer-staples

Bear of the Day: Eli Lilly (LLY)

by Kevin Cook Published on January 10,2023

Guidance for this year drags down analyst EPS estimates by nearly 10% to just 9% growth

LLYNegative Net Change

Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's

by Zacks Equity Research Published on January 09,2023

FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.